CAS 156918-64-8 | CT-2584-003 : CT-2584
(World's Largest Pharmaceutical Supplier)
- CAS Number: 156918-64-8
- Stock: 999g
- Assay: 0.00%
CAS 156918-64-8, also known as sitagliptin, is a medication used to treat type 2 diabetes. It works by increasing the levels of incretin hormones in the body, which lowers blood sugar levels after meals.
Sitagliptin was approved for use by the United States Food and Drug Administration (FDA) in 2006, and has since become widely prescribed. It is typically taken orally once a day, either alone or in combination with other diabetes medications.
In addition to its primary use in treating diabetes, sitagliptin has also been investigated for its potential use in treating other conditions. For example, some studies have suggested that it may be beneficial in treating non-alcoholic fatty liver disease, a condition characterized by the buildup of fat in the liver that can lead to inflammation and scarring.
Like all medications, sitagliptin can cause side effects. Some common side effects include headaches, upper respiratory tract infections, and nausea. In rare cases, it may also cause pancreatitis or severe joint pain.
Despite its potential side effects, sitagliptin has been shown to be an effective treatment for type 2 diabetes, helping to improve blood sugar control and reduce the risk of complications associated with the disease. As such, it is a valuable tool in the management of this chronic condition, and continues to be an important area of research and development in the field of diabetes care.